Navigation Links
Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine

SAN FRANCISCO, April 11, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that a seasonal influenza vaccine formulated with the company's Vaxfectin(TM) adjuvant generated up to 60-fold higher antibody responses than an unformulated vaccine at the same dose in a recently completed study in mice. Formulation of sanofi pasteur's Fluzone(R) commercial vaccine with Vaxfectin(TM) also allowed a nearly 10-fold reduction in vaccine dose while generating equivalent or better antibody responses compared with unformulated vaccine, even at the lowest doses tested. Alain P. Rolland, Pharm.D., Ph.D., the company's Senior Vice President of Product Development, presented the data at the Drug Delivery 2007 meeting (San Francisco, April 9 - 11).

Vical is developing its own Vaxfectin(TM)-formulated DNA vaccine designed to protect against emerging strains of influenza virus that have the potential to cause a pandemic. In previously reported studies conducted at St. Jude Children's Research Hospital, Vical's lead Vaxfectin(TM)-formulated, DNA vaccine candidate provided 100% protection in mice and ferrets against lethal challenges with a highly pathogenic strain of H5N1 influenza virus. Initial human testing of Vical's influenza DNA vaccine is expected to begin in the second half of 2007.

Vical tested the Vaxfectin(TM) adjuvant with Fluzone(R) seasonal influenza vaccine to evaluate its potential to ease the anticipated shortage of stockpiled pandemic influenza vaccine and the limited global vaccine manufacturing capacity. In separate studies conducted by others, stockpiled sanofi pasteur H5N1 pandemic influenza vaccine with no adjuvant achieved target levels of antibodies in less than half the subjects after two 90 mcg doses -- a total of six times the normal 15 mcg dose of each strain that provides 75% to 90% protection against seasonal influenza.

The new Fluzone(R) study data confirm and expan
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
3. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
9. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:9/18/2014)... ARBOR, Mich. , Sept. 18, 2014  A ... Research will allow the University of Michigan to establish ... The Glenn Center for Aging Research at ... evidence that drugs can slow the effects of aging ... unlock mechanisms of aging that can help develop medications ...
(Date:9/18/2014)... SAN DIEGO , Sept. 18, 2014 /PRNewswire/ ... today announced that the U.S. Food and Drug ... patient enrollment and dosing of PEGPH20 in SWOG,s ... is designed to evaluate Halozyme,s investigational drug PEGPH20 ... FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic ...
(Date:9/18/2014)... -- Australian biomarker discovery company Minomic International Ltd will ... prostate cancer screening test, planning to achieve US Food ... Minomic,s proprietary MiStat™ technology is a screening assay ... known as the MIL-38 antigen. This biomarker is present ... Researchers at 11 leading urology centres in ...
Breaking Medicine Technology:$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2
... , ALLEGAN, Mich. , Jan. 19 ... release financial results for its second quarter fiscal 2010 on Tuesday, ... Company will conduct a conference call at 10:00 a.m. (ET) ... Officer. , The conference call will be available live via webcast to ...
... LAKE CITY , Jan. 19 World Heart ... circulatory systems, announced today that the first U.S. implant of ... INTEGRIS Baptist Medical Center ("INTEGRIS") in Oklahoma City ... the first implant in the Levacor VAD bridge-to-transplant ("BTT") study, ...
Cached Medicine Technology:Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010 2WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City 2WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City 3
(Date:9/18/2014)... York and London. (PRWEB) September 18, 2014 ... of Computer Aided Engineering software, today announced its new ... will be utilizing the CD-adapco simulation tool, STAR-CCM+® in ... team just announced its participation in the 35th America’s ... the 35th edition of the America’s Cup is sustainability, ...
(Date:9/18/2014)... parents eat more vegetables and drink less sugar, according ... Columbia. But it,s still not enough, the study goes ... when it comes to eating healthier at school , ... of socioeconomic status, may inform a child,s diet. , ... some post-secondary education were 85 per cent more likely ...
(Date:9/18/2014)... in German . ... have won the ,International Space Station Research Competition, with ... prize, the scientists will see the International Space Station ... involves crystallizing two proteins of the hepatitis C virus ... the International Space Station is scheduled to lift off ...
(Date:9/18/2014)... September 18, 2014 Relias Learning, the leader ... human services markets, today announced it has been named to ... private companies in America. , In the three-year period from ... up almost 2,000 spots on the Inc. 5000 list to ... , “The industries we serve continue to grow, and ...
(Date:9/18/2014)... According to a new market report published by ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - ... at USD 77607.7 million in 2013 and is expected to ... to reach an estimated value of USD 115474.9 million in ... growing at a rapid pace due to increasing prevalence of ...
Breaking Medicine News(10 mins):Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2Health News:Kids eat better if their parents went to college 2Health News:Hepatitis C virus proteins in space 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4
... preventing medical support staff from completing orders for outpatient ... in a marked decrease in low-yield exams for patients, ... of Radiology . Many medical institutions request ... web-based radiology order entry systems. Some systems offer real-time ...
... and acceptance Three new reports describe biomarkers ... excellent and stable allograft function in the absence of ... transplants. Peter Heeger and Bernd Schrppel, at Mount Sinai ... commentary, the importance of these studies and how they ...
... ... its brain muscle by taking the top medal in SharpBrains first annual Brain Fitness ... ... its brain muscle by taking the top medal in SharpBrains first annual Brain Fitness ...
... predisposition to delivering early, , MONDAY, May 24 (HealthDay News) ... to give birth to a baby who isn,t full-term, a ... who weren,t born early but had one or more siblings ... researchers. , "There was a suspicion that preterm birth might ...
... To prevent rejection of their new kidneys, kidney transplant recipients ... lives. A handful of people, out of the thousands who ... drugs without losing their kidneys. Researchers studying these rare ... their white blood cells, which may one day be used ...
... kids with blood sugar disease , MONDAY, May 24 (HealthDay ... enteroviruses -- which can cause viral meningitis -- and diagnoses ... how the two might be linked, but the findings suggest ... for diabetes in its early stages, lead researcher Antonio Toniolo, ...
Cached Medicine News:Health News:Simple change results in fewer unnecessary imaging exams for patients 2Health News:JCI table of contents: May 24, 2010 2Health News:JCI table of contents: May 24, 2010 3Health News:JCI table of contents: May 24, 2010 4Health News:JCI table of contents: May 24, 2010 5Health News:JCI table of contents: May 24, 2010 6Health News:JCI table of contents: May 24, 2010 7Health News:JCI table of contents: May 24, 2010 8Health News:JCI table of contents: May 24, 2010 9Health News:USA Hockey Takes Gold at Brain Fitness Innovation Awards; Allstate & Nationwide Mutual Insurance Runners-up 2Health News:USA Hockey Takes Gold at Brain Fitness Innovation Awards; Allstate & Nationwide Mutual Insurance Runners-up 3Health News:USA Hockey Takes Gold at Brain Fitness Innovation Awards; Allstate & Nationwide Mutual Insurance Runners-up 4Health News:Women Born Early More Apt to Have Preterm Baby 2Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 2Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 3Health News:Viral Infection Could Be Marker for Type 1 Diabetes 2
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... ADx pacemaker family, which ... dual-chamber pacemaker, provides clinicians ... including the revolutionary AF ... U.S. commercially approved algorithm ...
... ADx pacemaker family, which includes ... provides clinicians with the most ... the revolutionary AF Suppression™ algorithm, ... commercially approved algorithm designed to ...
Medicine Products: